The Ziemer DCT technology

With our specialized know-how in ophthalmology, microtechnology, and information technology, we focus our research and development efforts as well as our commercial operations on ophthalmic surgery (refractive, cataract and glaucoma) and on ocular diagnostics (glaucoma and refractive/cornea).

We actively pursue partnerships, alliances and acquisitions that ensure our innovations reach eye care providers and patients quickly.

For our DCT technology we actively pursue partnerships or alliances in order to further develop the best solution for the early detection of glaucoma diseases.

Approximately 70 million people are affected by glaucoma disease, making it the second largest reason for blindness worldwide. The most important risk factor and only treatable factor for glaucoma is intraocular pressure (IOP). The Ziemer DCT technology enables physicians to accurately detect elevated IOP at a very early stage. The faster glaucoma is detected the quicker and more efficient will be the patient treatment.


The outstanding Ziemer DCT technology offers great and attractive opportunities for investment into a very attractive market:

  • The Ziemer DCT technology has been developed by SMT a corporate Ziemer spin off
  • The Ziemer DCT technology is already established on the glaucoma market with its PASCAL tonometer
  • 24 h IOP measurement itself is a half a billion US dollar market. The glaucoma market is a multi billion dollar market
  • The IP are protected by patents
  • Prototypes of the DCT lens are available

For companies that are already established in the glaucoma market, our DCT lens may be a great opportunity. Just because it enables to further develop the business of glaucoma treatments. It also offers the possibility to enter and develop new market segments like the segment of pre-glaucoma-detection.

Should you be interested in partnering with us, please feel free to contact us via the contact form. We are looking forward to it!